UBS Group
AARD

UBS Group’s Aardvark Therapeutics AARD Stock Holding History

UBS Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$595K Buy
157,888
+131,050
+488% +$1.36M ﹤0.01% 5960
2025
Q4 		$352K Sell
26,838
-27,890
-51% -$348K ﹤0.01% 6271
2025
Q3 		$727K Buy
54,728
+2,804
+5% +$31.6K ﹤0.01% 5816
2025
Q2 		$702K Buy
51,924
+37,219
+253% +$384K ﹤0.01% 5737
2025
Q1 		$110K Buy
+14,705
New +$165K ﹤0.01% 6976

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's AARD Position: Q1 2026 in Review

UBS Group increased its Aardvark Therapeutics (AARD) stake by 488% in Q1 2026, buying an estimated $1.36M and bringing the position to 157,888 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #5960.

UBS Group first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $727K in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • UBS Group held 157,888 shares of Aardvark Therapeutics worth $595K as of Q1 2026.
  • UBS Group bought 131,050 Aardvark Therapeutics shares in Q1 2026, an estimated $1.36M.
  • Aardvark Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5960 holding.
  • UBS Group first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • UBS Group's Aardvark Therapeutics position peaked at $727K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.